Clinical trial
Effect of Pioglitazone 15 mg or 30 mg on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
NCT00676260 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Pioglitazone 15 mg or 30 mg on Microcirculation in Type 2 Diabetes Patients Treated With Insulin
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2002
- Completion date
- August 31, 2004
- Enrollment
- 29 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.